Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: AMG 282, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Santa Monica, California • Aurora, Colorado • South Miami, Florida + 1 more

Conditions: Hepatic Impairment
Interventions: Iloperidone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Anaheim, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Cognitive Disorders
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: TAK-058, TAK-058 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austsitn, Texas

Conditions: Healthy
Interventions: clopidogrel, placebo, omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Recurrent Genital Herpes Simplex Type 2
Interventions: ABI-1179, ABI-1179 Placebo; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Kansas City, Missouri • Rochester, New York • Seattle, Washington

Conditions: Smallpox
Interventions: IMVAMUNE®, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 4,005 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Humanized anti-Factor Bb monoclonal antibody, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy Adults
Interventions: methylnaltrexone, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Obesity
Interventions: HM15275, Placebo of HM15275; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Alzheimer's Disease
Interventions: Velusetrag, Placebo; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy Volunteer
Interventions: Moxifloxacin, RO4917838, RO4917838 placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Homeostasis, Bone and Bones
Interventions: Dexlansoprazole, Esomeprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 75 Years · Female only
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Lakewood, Colorado + 9 more

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, Placebo; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: San Diego, California • College Station, Texas

Conditions: Healthy, Alzheimer Disease
Interventions: Lu AF87908, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 6
States / cities: Glendale, California • Hollywood, Florida • Miami, Florida + 3 more

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Pulmonary Arterial Hypertension
Interventions: KAR5585 Capsules, Placebo Capsules; Drug
Lead sponsor: Karos Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: HF1K16, Placebo; Drug
Lead sponsor: HighField Biopharmaceuticals Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy
Interventions: MTP-131 (Bendavia™); Drug
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: 5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Effect of Dexlansoprazole on Bone Homeostasis

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects